Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography

Journal of Virological Methods

Volumn 140, Issue 1-2, 2007, Pages 183-192

  Qu, Guang ^a,b   Bahr Davidson, Jennifer ^a   Prado, Joseph ^a   Tai, Alex ^a,b   Cataniag, Floro ^a   McDonnell, Jennifer ^a,b   Zhou, Jingmin ^b   Hauck, Bernd ^b   Luna, Jac ^a   Sommer, Jurg M ^a   Smith, Peter ^a   Zhou, Shangzhen ^a,b   Colosi, Peter ^a   High, Katherine A ^b   Pierce, Glenn F ^a   Wright, J Fraser ^a,b  

^a Avigen Inc   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Adeno associated virus; Column chromatography; Empty capsids

Indexed keywords

ACETIC ACID; AMMONIUM ACETATE; PARVOVIRUS VECTOR; SEPHAROSE;

ADENO ASSOCIATED VIRUS; ANION EXCHANGE; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CATION EXCHANGE; NONHUMAN; PRIORITY JOURNAL; VIRUS CAPSID; VIRUS ISOLATION; VIRUS PARTICLE;

CAPSID; CHROMATOGRAPHY, ION EXCHANGE; DEPENDOVIRUS; GENETIC VECTORS; HYDROGEN-ION CONCENTRATION; VIRION;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 2; MIRIDAE;

EID: 33846636272     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2006.11.019     Document Type: Article

References (34)

1. Bankiewicz K.S., Eberling J.L., Kohutnicka M., Jagust W., Pivivrotto P., Bringas J., and Cunningham J. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp. Neurol. 164 (2000) 2-14
2. Brument N., Morenweiser R., Blouin V., Toublance E., Raimbaud I., Cherel Y., Folliot S., Gaden F., Boulannnger P., Kroner-Lux G., Moullier P., Rolling F., and Salvetti A. A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5. Mol. Ther. 6 (2002) 678-686
3. Burton M., Nakai H., Colosi P., Cunningham J., Mitchell R., and Couto L. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 12725-12730
4. Chao H., Mao L., Bruce A.T., and Walsh C.E. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood 95 (2000) 1594-1599
5. Clark K.R., Liu X., Mcgrath J.P., and Johnon P.R. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum. Gene Ther. 10 (1999) 1031-1039
6. Davdoff A.M., Ng C.Y., Sleep S., Gray J., Azam S., Zhao Y., Mcintosh J.H., Karimipoor M., and Nathwani A.C. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J. Virol. Methods 121 (2004) 209-215
7. During M.J., Kaplitt M.G., Stern M.B., and Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum. Gene Ther. 12 (2001) 1589-1591
8. Flotte T.R., Bantly M.L., Spencer L.T., Byrne B.J., Spence C.T., Baker D.J., and Humphries M. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum. Gene Ther. 15 (2004) 93-128
9. Gao G., Qu G., Burnham M.S., Huang J., Chirmule N., Joshi B., Yu Q.C., Marsh J.A., Concicao C.M., and Wilson J.M. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum. Gene Ther. 11 (2000) 2079-2091
10. Graham F.L., and van der Eb A.J. A new technique for assay of infectivity of human adenovirus 5 DNA. Virology 52 (1973) 456-467
11. Grimm D., Kern A., Pawlita M., Ferari F., Samulski R., and Klenschmidt J. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6 (1999) 1322-1330
12. Grimm D., Zhou S., Nakai H., Thomas C.E., Storm T.A., Fuess S., Matsushita T., Allen J., Surosky R., Lochrie M., Meuse L., McClelland A., Colosi P., and Kay M.A. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102 (2003) 2412-2419
13. Herzog R.W., Hagstrom J.N., Kung S.H., Tai S.J., Wilson J.M., Fisher K.J., and High K.A. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 3809-5804
14. Kaludov N., Handelman B., and Chirini J.A. Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum. Gene Ther. 13 (2002) 1235-1243
15. Kay M.A., Manno C.S., Ragni M.V., Larson P.J., Couto L.B., McClelland A., Glader B., Chew A.J., Tai S.J., Herzog R.W., Arruda V., Johnson F., Scallan C., Skarsgard E., Flake A.W., and High K.A. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24 (2000) 257-261
16. Kessler P.D., Podsakoff G.M., Chen X., Mcquiston S.A., Colosi P.C., Matelis L.A., Kurtzman G.J., and Byrne B.J. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 14082-14087
17. Lewis U.J., Cheever E.V., and Hopkins W.C. Kinetic study of the deamidation of growth hormone and prolactin. Biochim. Biophys. Acta 214 (1970) 498-508
18. Manno C.S., Chew A.J., Hutchison S., Larson P.J., Herzog R.W., Arruda V.R., Tai S.J., Ragni M.V., Thompson A., Ozelo M., Cotto L.B., Leonard D.G., Johnson F.A., McClelland A., Scallan C., Skarsgard E., Flake A.W., Kay M.A., High K.A., and Glader B. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101 (2003) 2963-2972
19. Manno C.S., Arruda V.R., Pierce G.F., Ragni M., Rasko J., Ozelo M.C., Hoots K., Blatt P., Konkle B., Dake M., Kaye R., Razavi M., Zakjo A., Zehnder J., Nakai H., Chew A., Leonard D., Wright J.F., Lessard R.R., Sommer J.M., Tiggees M., Sabatono D., Luke A., Jiang H., Mingozzi F., Couto L., Ertl H.C., High K.A., and Kay M.A. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations of imposed by the host immune response. Nat. Med. 12 (2006) 342-347
20. Matsushita T., Elliger S., Elliger C., Podsakoff G., Villarreal L., Kurtzman G.J., Iwaki Y., and Colosi P. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5 (1998) 938-945
21. Nakai H., Herzog R.W., Hagstrom J.N., Walter J., Kung S.H., Yang R.Y., Tai S.J., Iwaki Y., Kurtzman G.J., Fisher K.J., Colosi P., Couto L.B., and High K.A. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 91 (1998) 4600-4607
22. Passini M.A., Watson D.J., Vite C.H., Landsburg D.J., Feigenbaum A.L., and Wolfe J.H. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J. Virol. 77 (2003) 7034-7040
23. Potter M., Chestnut K., Muzyczka N., Flotte T., and Zolotukhin S. Streamlined large-scale production of recombinant adeno-associated virus (rAAV) vectors. Methods Enzymol. 346 (2002) 413-430
24. Sabatino D.E., Mingozzi F., Hui K.J., Chen H., Colosi P., Ertl H.C., and High K.A. Identification of mouse AAV capsid-specific CD8 + T cell epitopes. Mol. Ther. 12 (2005) 1023-1033
25. Smith R.H., Ding C., and Kotin R.M. Serum-free production and column purification of adeno-associated virus type 5. J. Virol. Methods 114 (2003) 115-124
26. Snyder R.O., and Flotte T.R. Production of clinical-grade recombinant adeno-associated virus vectors. Curr. Opin. Biotechnol. 13 (2002) 418-423
27. Sommer J.M., Smith P.H., Parthasarathy S., Isaacs J., Vijay S., Kieran J., Powell S.K., McClelland A., and Wright J.F. Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol. Ther. 7 (2003) 122-128
28. Summerford C., and Samulski R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72 (1998) 1438-1445
29. Urabe M., Xin K.Q., Obara Y., Nakkura T., Mizukami H., Kume A., Okuda K., and Ozawa K. Removal of empty particles from type 1 adeno-associated virus vector stocks by ion exchange chromatography potentiates transgene expression. Mol. Ther. 13 (2006) S427
30. Wagner J.A., Nepomuceno I.B., Messner A.H., Moran M.L., Batson E.P., Dimicell S., Brown B.W., Desch J.K., Norbash A.M., Conard C.K., Guggino W.B., Flotter T.R., Wine J.J., Carter B.J., Reynolds T.C., Moss R.B., and Gardner P. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum. Gene Ther. 13 (2002) 1349-1359
31. Wright J.F., Le T., Prado J., Bahr-Davidson J., Smith P.H., Zhen Z., Sommer J.M., Pierce G.F., and Qu G. Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. Mol. Ther. 12 (2005) 171-178
32. Wu X. A novel method for purification of recombinant adeno-associated virus vectors on a large scale. Chin. Sci. Bull. 46 (2001) 485-489
33. Zhou S., Murphy J.E., Escobedo J.A., and Dwarki V.J. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates. Gene Ther. 5 (1998) 665-670
34. Zolotukhin S., Potter M., Zolotukhin I., Sakai Y., Loiler S., Fraites T.J.J.R., Chiodo V.A., Philpsberg T., Muzyczka N., Hausirth W.W., Flotter T.R., Byrne B.J., and Snyder R.O. Production and purification of serotypes 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002) 58-67